Delivery of floxuridine derivatives to cancer cells by water-soluble organometallic cages

Bioconjugate Chemistry

Volumn 23, Issue 3, 2012, Pages 461-471

  Yi, Jeong Wu ^a   Barry, Nicolas P E ^b   Furrer, Mona A ^b   Zava, Olivier ^c   Dyson, Paul J ^c   Therrien, Bruno ^b   Kim, Byeang Hyean ^a  

^a Pohang University of Science and Technology (POSTECH)   (South Korea)

^b UNIVERSITÉ DE NEUCHÂTEL   (Switzerland)

^c EPFL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMOLECULES; CELLS; DISEASES; ORGANOMETALLICS; RUTHENIUM COMPOUNDS; SELF ASSEMBLY;

BUILDING BLOCKES; CANCER CELLS; CARCEPLEX; CYTOTOXIC; DEOXYURIDINE; HOST-GUEST COMPOUND; HYDROPHOBIC CAVITIES; NUCLEOSIDE DERIVATIVES; P-CYMENE; WATERSOLUBLE;

PYRENE;

1,4 BENZOQUINONE DERIVATIVE; 1,4 NAPHTHOQUINONE DERIVATIVE; BRIDGED COMPOUND; CISPLATIN; DEOXYURIDINE DERIVATIVE; FLOXURIDINE DERIVATIVE; NUCLEOSIDE DERIVATIVE; ORGANOMETALLIC COMPOUND; PARA CYMENE; PYRENE DERIVATIVE; RUTHENIUM DERIVATIVE; TRIAZINE DERIVATIVE; WATER;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; ELECTROSPRAY MASS SPECTROMETRY; ENCAPSULATION; FEMALE; HUMAN; HUMAN CELL; HYDROPHOBICITY; IC 50; PROTON NUCLEAR MAGNETIC RESONANCE; SOLUBILITY;

EID: 84863337900     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc200472n     Document Type: Article

References (39)

1. Galmarini, C. M., Mackey, J. R., and Dumontet, C. (2001) Nucleoside analogues: mechanisms of drug resistance and reversal strategies Leukemia 15, 875-890 (Pubitemid 32529886)
2. Longley, D. B., Harkin, D. P., and Johnston, P. G. (2003) 5-Fluorouracil: mechanisms of action and clinical strategies Nat. Rev. Cancer 3, 330-338 (Pubitemid 37328853)
3. Thomas, D. M. and Zalcberg, J. R. (1998) 5-Fluorouracil: a pharmacological paradigm in the use of cytotoxics Clin. Exp. Pharmacol. Physiol. 25, 887-895 (Pubitemid 28500827)
4. Nakagawa, H., Maeda, N., Tsuzuki, T., Suzuki, T., Hirayama, A., Miyahara, E., and Wada, K. (2001) Intracavitary chemotherapy with 5-fluoro-2′- deoxyuridine (FdUrd) in malignant brain tumor Jpn. J. Clin. Oncol. 31, 251-258 (Pubitemid 32743250)
5. Landowski, C. P., Song, X., Lorenzi, P. L., Hilfinger, J. M., and Amidon, G. L. (2005) Floxuridine amino acid ester prodrugs: enhancing Caco-2 permeability and resistance to glycosidic bond metabolism Pharm. Res. 22, 1510-1518 (Pubitemid 41215891)
6. Tsume, Y., Hilfinger, J. M., and Amidon, G. L. (2008) Enhanced cancer cell growth inhibition by dipeptide prodrugs of floxuridine: increased transporter affinity and metabolic stability Mol. Pharmaceutics 5, 717-727
7. Senanayake, T. H., Warren, G., and Vinogradov, S. V. (2011) Novel anticancer polymeric conjugates of activated nucleoside analogues Bioconjugate Chem. 22, 1983-1993
8. Østergaard, M. E. and Hrdlicka, P. J. (2011) Pyrene-functionalized oligonucleotides and locked nucleic acids (LNAs): tools for fundamental research, diagnostics, and nanotechnology Chem. Soc. Rev. 40, 5771-5788
9. Guckian, K. M., Schweitzer, B. A., Ren, R. X.-F., Sheils, C. J., Tahmassebi, D. C., and Kool, E. T. (2000) Factors contributing to aromatic stacking in water: evaluation in the context of DNA J. Am. Chem. Soc. 122, 2213-2222 (Pubitemid 30164632)
10. Baba, M., Saitoh, M., Kowaka, Y., Taguma, K., Yoshida, K., Semba, Y., Kasahara, S., Yamanaka, T., Ohshima, Y., Hsu, Y.-C., and Lin, S. H. (2009) Vibrational and rotational structure and excited-state dynamics of pyrene J. Chem. Phys. 131, 224318
11. Saito, I., Saito, Y., Hanawa, K., Hayashi, K., Motegi, K., Sekhar Bag, S., Dohno, C., Ichiba, T., Tainaka, K., and Okamoto, A. (2006) Highly selective fluorescent nucleobases for designing base-discriminating fluorescent probes Pure Appl. Chem. 78, 2305-2312
12. Lee, I. J., Yi, J. W., and Kim, B. H. (2009) Probe for i-motif structure and G-rich strands using end-stacking ability Chem. Commun. 5383-5385
13. Seo, Y. J., Lee, I. J., and Kim, B. H. (2009) Homoadenine signaling system for SNP typing Mol. BioSyst. 5, 235-237
14. Jeong, H. S., Kang, S., Lee, J. Y., and Kim, B. H. (2009) Probing specific RNA bulge conformations by modified fluorescent nucleosides Org. Biomol. Chem. 7, 921-925
15. Seo, Y. J., Lee, I. J., Yi, J. W., and Kim, B. H. (2007) Probing the stable G-quadruplex transition using quencher-free and-stacking ethynyl pyrene-adenosine Chem. Commun. 2817-2819 (Pubitemid 47035574)
16. py-substituted oligodeoxyadenylate and its unique fluorescence J. Am. Chem. Soc. 129, 5244-5247 (Pubitemid 46651402)
17. Seo, Y. J., Jeong, H. S., Bang, E.-K., Hwang, G. T., Jung, J. H., Jang, S. K., and Kim, B. H. (2006) Cholesterol-linked fluorescent molecular beacons with enhanced cell permeability Bioconjugate Chem. 17, 1151-1155 (Pubitemid 44455322)
18. Kurreck, J. (2009) RNA interference: from basic research to therapeutic applications Angew. Chem., Int. Ed. 48, 1378-1398
19. Hartinger, C. G., Zorbas-Seifried, S., Jakupec, M. A., Kynast, B., Zorbas, H., and Keppler, B. K. (2006) From bench to bedside - preclinical and early clinical development of the anticancer agent indazolium trans- [tetraclhorobis(1 H -indazole)ruthenate(III) (KP1019 or FFC14A) J. Inorg. Biochem. 100, 891-904 (Pubitemid 44308176)
20. Jakupec, M. A., Galanski, M., Arion, V. B., Hartinger, C. G., and Keppler, B. K. (2008) Antitumour metal compounds: more than theme and variations Dalton Trans. 183-194 (Pubitemid 350278321)
21. Hartinger, C. G. and Dyson, P. J. (2009) Bioorganometallic chemistry - from teaching paradigms to medicinal applications Chem. Soc. Rev. 38, 391-401
22. Süss-Fink, G. (2010) Arene ruthenium complexes as anticancer agents Dalton Trans. 39, 1673-1688
23. Smith, G. S. and Therrien, B. (2011) Targeted and multifunctional arene ruthenium chemotherapeutics Dalton Trans. 40, 10793-10800
24. Mendoza-Ferri, M.-G., Hartinger, C. G., Eichinger, R. E., Stolyarova, N., Severin, K., Jakupec, M. A., Nazarov, A. A., and Keppler, B. K. (2008) Influence of the spacer length on the in vitro anticancer activity of dinuclear ruthenium-arene compounds Organometallics 27, 2405-2407
25. Mendoza-Ferri, M. G., Hartinger, C. G., Mendoza, M. A., Groessl, M., Egger, A. E., Eichinger, R. E., Mangrum, J. B., Farrell, N. P., Maruszak, M., Bednarski, P. J., Klein, F., Jakupec, M. A., Nazarov, A. A., Severin, K., and Keppler, B. K. (2009) Transferring the concept of multinuclearity to ruthenium complexes for improvement of anticancer activity J. Med. Chem. 52, 916-925
26. Mendoza-Ferri, M. G., Hartinger, C. G., Nazarov, A. A., Eichinger, R. E., Jakupec, M. A., Severin, K., and Keppler, B. K. (2009) Influence of the arene ligand, the number and type of metal centers, and the leaving group on the in vitro antitumor activity of polynuclear organometallic compounds Organometallics 28, 6260-6265
27. Therrien, B. (2009) Arene ruthenium cages: boxes full of surprises Eur. J. Inorg. Chem. 2445-2453
28. Vajpayee, V., Yang, Y. J., Kang, S. C., Kim, H., Kim, I. S., Wang, M., Stang, P. J., and Chi, K.-W. (2011) Hexanuclear self-assembled arene-ruthenium nano-prismatic cages: potential anticancer agents Chem. Commun. 47, 5184-5186
29. Pitto-Barry, A., Barry, N. P. E., Zava, O., Deschenaux, R., Dyson, P. J., and Therrien, B. (2011) Double targeting of tumours with pyrenyl-modified dendrimers encapsulated in an arene-ruthenium metallaprism Chem. - Eur. J. 17, 1966-1971
30. Pitto-Barry, A., Barry, N. P. E., Zava, O., Deschenaux, R., and Therrien, B. (2011) Encapsulation of pyrene-functionalized poly(benzyl ether) dendrons into a water-soluble organometallic cage Chem. Asian J. 6, 1595-1603
31. 6+: a Trojan horse for cancer cells Angew. Chem., Int. Ed. 47, 3773-3776
32. Mattsson, J., Govindaswamy, P., Furrer, J., Sei, Y., Yamaguchi, K., Süss-Fink, G., and Therrien, B. (2008) Encapsulation of aromatic molecules in hexanuclear arene ruthenium cages: a strategy to build up organometallic carceplex prisms with a dangling arm standing out Organometallics 27, 4346-4356
33. Mattsson, J., Zava, O., Renfrew, A. K., Sei, Y., Yamaguchi, K., Dyson, P. J., and Therrien, B. (2010) Drug delivery of lipophilic pyrenyl derivatives by encapsulation in a water soluble metalla-cage Dalton Trans. 39, 8248-8255
34. 6+ Eur. J. Inorg. Chem. 4695-4700
35. Barry, N. P. E., Zava, O., Dyson, P. J., and Therrien, B. (2011) Excellent correlation between drug release and portal size in metalla-cage drug delivery systems Chem. - Eur. J. 17, 9669-9677
36. Zava, O., Mattsson, J., Therrien, B., and Dyson, P. J. (2010) Evidence for drug release from a metalla-cage delivery vector following cellular internalization Chem. - Eur. J. 16, 1428-1431
37. Sun, Y.-W., Chen, K.-M., and Kwon, C.-H. (2006) Sulfonyl-containing nucleoside phosphotriesters and phosphoramidates as novel anticancer prodrugs of 5-fluoro-2′-deoxyuridine 5′-monophosphate (FdUMP) Mol. Pharmaceutics 3, 161-173 (Pubitemid 43672252)
38. Anderson, H. L., Anderson, S., and Sanders, J. K. M. (1995) Ligand binding by butadiyne-linked porphyrin dimers, trimers and tetramers J. Chem. Soc., Perkin Trans. 1 2231-2245
39. Therrien, B. (2011) Coordination chemistry of 2,4,6-tri(pyridyl)-1,3,5- triazine ligands J. Organomet. Chem. 696, 637-651